ElsaLys Biotech
Quick facts
Phase 3 pipeline
- Inolimomab (Leukotac) · Immunology
Inolimomab is a monoclonal antibody that blocks the IL-2 receptor alpha chain (CD25) on T cells to suppress excessive immune activation.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: